Business
Orthocell Secures Approval to sell Remplir™ to the U.S. Department of Defence Hospital Network
Regenerative medicine company Orthocell Limited (ASX: OCC, "Orthocell" or the "Company") is pleased to announce it has secured approval for its Remplir™ nerve repair device to be used across the United States Department of Defence (DoD) and Veterans Affairs (VA) hospital networks.
About this update from Optical Cable Corporation
[{"type":"list","items":[{"val":[{"type":"text","content":"Orthocell receives approval for Remplir™ to be used across the United States Department of Defence (DoD) and Veterans Affairs (VA) hospital networks, comprising:","length":161,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"51 DoD military hospitals; and","length":30,"tagName":"p"}]},{"val":[{"type":"text","content":"170 Veterans Affairs (VA) medical centres","length":41,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":71,"olType":false}]},{"val":[{"type":"text","content":"For context, Orthocell has already secured 32 Value Analysis Committee (VAC) approvals providing access to over 115 hospitals, with a further 57 VAC applications currently pending approval[1]","length":191,"tagName":"p"}]},{"val":[{"type":"text","content":"Orthocell will now leverage its existing U.S. distributor network to target military and VA surgeons operating within these hospital systems. The Company's distributor network currently covers 17 states","length":206,"tagName":"p"}]},{"val":[{"type":"text","content":"This approval comes at a time when Orthocell is seeing clear evidence of increasing commercialisation and revenue momentum in the U.S. market","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Remplir has already demonstrated its value in conflict-related injuries in Ukraine, with multiple surgical procedures performed, highlighting its suitability for the types of trauma commonly encountered within military healthcare systems","length":237,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1007,"olType":false},{"type":"text","content":"PERTH, Australia, April 16, 2026 /PRNewswire/ -- Regenerative medicine company Orthocell Limited (ASX: OCC, "Orthocell" or the "Company") is pleased to announce it has secured approval for its Remplir™ nerve repair device to be used across the United States Department of Defence (DoD) and Veterans Affairs (VA) hospital networks.","length":350,"tagName":"p"},{"type":"image","alt":"Orthocell logo (PRNewsfoto/Orthocell Ltd)","displaySize":"","headline":null,"caption":"Orthocell logo (PRNewsfoto/Orthocell Ltd)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":151,"url":"https://media.zenfs.com/en/prnewswire.com/aaf5effce90c758f385d111d3c425a53"},"resized":{"url":"ht...